<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656057</url>
  </required_header>
  <id_info>
    <org_study_id>GALINKUR</org_study_id>
    <nct_id>NCT01656057</nct_id>
  </id_info>
  <brief_title>The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion</brief_title>
  <official_title>The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Filip Krag Knop</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The last couple of years it has been shown that bile acids not only acts as simple
      emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an
      influence on fat digestion and lipid metabolism, but also modulates the energy expenditure in
      (brown) adipose tissue and muscle tissue. This action is due to stimulation of the receptor
      TGR5 by bile acids. Recently scientists have discovered that this receptor in rodents is also
      expressed on the surface of intestinal L-cells (which normally secrets Glucagon-Like
      Peptide-1 (GLP-1) in response to nutrient stimulation). The stimulation of this receptor has
      shown a GLP-1 secretion from the intestinal cells which is interesting since GLP-1 has a
      central role in maintaining normal glucose tolerance and thus blood sugar. Given the above,
      bile acids has an important impact on intestinal GLP-1 secretion. Whether these scientific
      findings can be proven in human beings is uncertain.

      The primary hypothesis is that stimulating gall bladder emptying via Cholecystokinin (CCK) in
      healthy subjects will result in a significant GLP-1 response. We also hypothesize that adding
      orally Metformin or a sequestrant (&quot;a bile acid binder&quot;) will further enhance this GLP-1
      response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GLP-1 response as incremental area under curve (iAUC)</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>c-peptide</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>glucagon</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon-Like Peptide-2</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peptide YY</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Oxyntomodulin</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucose-Dependent Insulinotropic Peptide</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bile acids</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gastrin</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CCK</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gall bladder emptying assessed ultrasonically</measure>
    <time_frame>-30, -15, 20, 40, 60, 90, 120, 150, 180</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>-10, 50, 210</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Estimation of satiety via visual analogue scale</measure>
    <time_frame>0, 30, 60, 90, 120, 150, 180, 240</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion</condition>
  <arm_group>
    <arm_group_label>Acetaminophen+saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen+CCK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin+saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin+CCK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colesevelam+saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colesevelam+CCK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen dissolved in 50 ml of water</description>
    <arm_group_label>Acetaminophen+saline</arm_group_label>
    <arm_group_label>Acetaminophen+CCK</arm_group_label>
    <arm_group_label>Metformin+saline</arm_group_label>
    <arm_group_label>Metformin+CCK</arm_group_label>
    <arm_group_label>Colesevelam+saline</arm_group_label>
    <arm_group_label>Colesevelam+CCK</arm_group_label>
    <other_name>Paracetamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin + acetaminophen dissolved in 50 ml of water</description>
    <arm_group_label>Metformin+saline</arm_group_label>
    <arm_group_label>Metformin+CCK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>Colesevelam + acetaminophen dissolved in 50 ml of water</description>
    <arm_group_label>Colesevelam+saline</arm_group_label>
    <arm_group_label>Colesevelam+CCK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cholecystokinin-8</intervention_name>
    <description>iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes</description>
    <arm_group_label>Acetaminophen+CCK</arm_group_label>
    <arm_group_label>Metformin+CCK</arm_group_label>
    <arm_group_label>Colesevelam+CCK</arm_group_label>
    <other_name>CCK-8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>iv. saline infusion 40 ml/hour for the first 60 minutes</description>
    <arm_group_label>Acetaminophen+saline</arm_group_label>
    <arm_group_label>Metformin+saline</arm_group_label>
    <arm_group_label>Colesevelam+saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c &lt; 6,0%

          -  Not anaemic

          -  Written informed consent

        Exclusion Criteria:

          -  Liver disease

          -  Nephropathy

          -  fasting plasma glucose &gt; 5,6mM

          -  Diabetes running in the family (parents or grandparents)

          -  Any medical treatment

          -  A former medical history of liver- or bile disease

          -  any surgical procedure conducted in the abdomen

          -  Body mass index &lt; 18,5 kg/m2 or &gt; 25 kg/m2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Rohde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetic Research Division, Department of Internal Medicine, University Hospital of Copenhagen, Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Copenhagen, Gentofte Hospital, Diabetic Research Division</name>
      <address>
        <city>Copenhagen, Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>July 10, 2015</last_update_submitted>
  <last_update_submitted_qc>July 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>MD, Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Bile acids</keyword>
  <keyword>Gall bladder emptying</keyword>
  <keyword>Human</keyword>
  <keyword>Glucagon like peptide 1</keyword>
  <keyword>GLP-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Cholecystokinin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

